Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M31,791Revenue $M2,604Net Margin (%)5.5Altman Z-Score4.5
Enterprise Value $M33,982EPS $0.8Operating Margin %20.6Piotroski F-Score3
P/E(ttm)115Beneish M-Score-2.1Pre-tax Margin (%)19.1Higher ROA y-yN
Price/Book3.710-y EBITDA Growth Rate %--Quick Ratio2.9Cash flow > EarningsY
Price/Sales11.75-y EBITDA Growth Rate %52.3Current Ratio3.2Lower Leverage y-yN
Price/Free Cash Flow58.1y-y EBITDA Growth Rate %-15.2ROA % (ttm)1.5Higher Current Ratio y-yN
Dividend Yield %--PEG2.2ROE % (ttm)2.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M225ROIC % (ttm)2.1Gross Margin Increase y-yN

Gurus Latest Trades with ALXN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALXNDavid Swensen 2015-09-30 Sold Out -16.37%$145.6 - $207.84
($182.41)
$ 141.11-23%Sold Out0
ALXNRon Baron 2015-09-30 Reduce-0.03%$145.6 - $207.84
($182.41)
$ 141.11-23%Reduce -53.24%32,624
ALXNMario Gabelli 2015-09-30 Sold Out $145.6 - $207.84
($182.41)
$ 141.11-23%Sold Out0
ALXNDavid Swensen 2015-06-30 Buy 16.37%$155.01 - $190.92
($172.58)
$ 141.11-18%New holding319,273
ALXNJoel Greenblatt 2015-06-30 Sold Out -0.03%$155.01 - $190.92
($172.58)
$ 141.11-18%Sold Out0
ALXNRon Baron 2015-06-30 Add0.02%$155.01 - $190.92
($172.58)
$ 141.11-18%Add 69.48%69,764
ALXNMario Gabelli 2015-06-30 Buy $155.01 - $190.92
($172.58)
$ 141.11-18%New holding1,415
ALXNJoel Greenblatt 2015-03-31 Reduce-0.09%$171.42 - $189.07
($181.01)
$ 141.11-22%Reduce -72.94%23,261
ALXNRon Baron 2015-03-31 Add0.02%$171.42 - $189.07
($181.01)
$ 141.11-22%Add 124.13%41,163
ALXNJoel Greenblatt 2014-12-31 Add0.13%$159.46 - $200.79
($185.68)
$ 141.11-24%Add 4665.74%85,974
ALXNRon Baron 2014-12-31 Add$159.46 - $200.79
($185.68)
$ 141.11-24%Add 41.92%18,366
ALXNJoel Greenblatt 2014-09-30 Reduce-0.03%$155.06 - $173.08
($164.22)
$ 141.11-14%Reduce -89.45%1,804
ALXNRon Baron 2014-09-30 Add$155.06 - $173.08
($164.22)
$ 141.11-14%Add 27.56%12,941
ALXNJoel Greenblatt 2014-06-30 Add0.02%$139.61 - $170.2
($157.93)
$ 141.11-11%Add 240.11%17,094
ALXNJoel Greenblatt 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 141.11-11%New holding5,026
ALXNRon Baron 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 141.11-11%New holding10,218
ALXNJoel Greenblatt 2013-03-31 Sold Out -0.07%$83.39 - $102.57
($93.13)
$ 141.1152%Sold Out0
ALXNJoel Greenblatt 2012-12-31 Buy 0.07%$87.97 - $118.15
($98.27)
$ 141.1144%New holding12,977
ALXNGeorge Soros 2012-06-30 Sold Out -0.07%$83.74 - $98.82
($91.04)
$ 141.1155%Sold Out0
ALXNGeorge Soros 2012-03-31 Buy 0.07%$70.29 - $94.31
($75.85)
$ 141.1186%New holding50,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALXN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ALXN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Moriarty John BEVP & General Counsel 2016-02-08Sell4,602$140.380.52view
Hallal DavidCEO 2016-02-08Sell11,297$140.50.43view
Wagner Heidi LSVP, Global Government Affairs 2016-02-08Sell2,108$140.930.13view
Carmichael ClareEVP, Chief HR Officer 2016-02-08Sell4,865$139.820.92view
BELL LEONARDDirector 2016-02-08Sell15,872$139.581.1view
Islam SaqibEVP, Chief Strat & Port. Off. 2016-02-08Sell3,444$141.17-0.04view
Sinha VikasEVP & CFO 2016-02-08Sell6,547$140.040.76view
MACKAY MARTINEVP & Global Head of R&D 2016-02-08Sell4,071$139.980.81view
O'Neill JulieEVP. Global Operations 2016-02-08Sell2,858$141.83-0.51view
Miller EdwardSVP, Chief Compliance Officer 2016-02-05Sell1,051$143.02-1.34view

Quarterly/Annual Reports about ALXN:

News about ALXN:

Articles On GuruFocus.com
Baron Funds Comments on Alexion Pharmaceuticals Feb 08 2016 
Weekly CFO Sales Highlight: H&R Block, DISH Network, Alexion Pharmaceuticals Jan 03 2016 
Weekly CFO Sells Highlight: Tyson Foods, Alexion Pharmaceuticals, Gilead Sciences Dec 13 2015 
Weekly Insider Sells Highlights: CDW, Twitter, P&G, Alexion Pharmaceuticals Dec 10 2015 
Alexion Pharmaceuticals Loses Position in Swensen's Portfolio Dec 03 2015 
Jim Simons' Largest Adds of the 3rd Quarter Nov 13 2015 
Baron Funds Comments on Alexion Pharmaceuticals Inc. Nov 10 2015 
Frank Sands Shows Bold Side in Second-Quarter Trades Sep 13 2015 
David Swensen Buys Stake in Vanguard MSCI Emerging Markets ETF Aug 19 2015 
Baron Funds Comments on Alexion Pharmaceuticals Inc. Aug 19 2015 

More From Other Websites
ALEXION PHARMACEUTICALS INC Financials Feb 12 2016
Morgan Stanley is Wrong: This Biotech is Ready to Explode Higher Feb 11 2016
The Zacks Analyst Blog Highlights: Regeneron, Alexion, CTI BioPharma, BioCryst and Sarepta Feb 11 2016
Biotech ETFs Slide as Stocks Report Mixed Q4 Results Feb 09 2016
ALEXION PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 08 2016
Alexion Pharmaceuticals' Big Top Foreshadows Big Drop Feb 08 2016
How to Play the Biotech Selloff Feb 05 2016
Alexion Pharmaceuticals, Inc. Earnings Analysis: 2015 By the Numbers Feb 04 2016
Alexion to Present at the Leerink Partners 5th Annual Global Healthcare Conference Feb 04 2016
Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.3% Feb 04 2016
Lightning Round: This energy stock goes higher Feb 03 2016
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 03 2016
Edited Transcript of ALXN earnings conference call or presentation 3-Feb-16 3:00pm GMT Feb 03 2016
Alexion Pharmaceuticals Rides the Earnings Roller Coaster Feb 03 2016
Alexion Misses on Earnings and Revenues in Q4, Gives View Feb 03 2016
[$$] Alexion Pharmaceuticals Revenue Jumps, Profit Falls Feb 03 2016
Biotechnology Stocks Technical Snapshot -- Geron, ACADIA Pharma, Alexion Pharma, and Illumina Feb 03 2016
Alexion (ALXN) Misses on Q4 Earnings and Revenues Feb 03 2016
Morning Movers: Alexion, Merck Drop on Earnings; Atwood Oceanics Gains Feb 03 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK